Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy

Abstract

Objective Patients with acute coronary syndrome are treated with dual antiplatelet therapy containing acetylsalicylic acid (ASA) and P2Y12 antagonists. In case of urgent coronary artery bypass grafting this might be associated with increasing risks of bleeding complications.

Methods Data from 1200 consecutive urgent operations between 2010 and 2018 were obtained from our institutional patient database. For this study off-pump surgery was excluded. The primary composite end point major bleeding consisted of at least one end point: transfusion ≥ 5 packed red blood cells within 24 hours, rethoracotomy due to bleeding, chest tube output >2000 mL within 24 hours. Demographic data, peri-, and postoperative variables and outcomes were compared between patients treated with mono antiplatelet therapy, ASA + clopidogrel (ASA-C) +ticagrelor (ASA-T) or +prasugrel (ASA-P) < 72 hours before surgery. Furthermore, we compared patients with dual antiplatelet therapy with ASA monotherapy.

Results From 1,086 patients, 475 (44%) received dual antiplatelet therapy. Three-hundred seventy-two received ASA-C (77.7%), 72 ASA-T (15%), and 31 ASA-P (6.5%). Major bleeding (44 vs. 23%, p < 0.0001) was more frequently in patients receiving dual therapy with higher rates of massive drainage loss within 24 hours (23 vs. 11%, p < 0.0001) of mass transfusion (34 vs. 16%, p < 0.0001) and rethoracotomy (10 vs. 5%, p = 0.002) when compared with ASA. In this analysis, ASA-T and ASA-P were not associated with higher bleeding complications compared with ASA-C.

Conclusion Dual antiplatelet therapy is associated with higher rates of major bleeding. Further studies should examine the difference in the prevalence of major bleeding complications in the different dual antiplatelet therapy regimes in patients requiring urgent surgery.

Keywords

coronary artery bypass grafts surgery - CABG - myocardial infarction (includes complications; e.g. - rupture) - blood - antiplatelet

^* Both authors contributed equally to this work.

Publication History

Received: 18 January 2020

Accepted: 21 February 2020

Article published online:
27 June 2020

• References

• 1 Ibanez BJS, Agewall S, Antunes MJ. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology. Eur Heart J 2018; 39 (02) 119-177
• 2 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
• 3 Wiviott SD, Braunwald E, McCabe CH. et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
• 4 Hansson EC, Rexius H, Dellborg M, Albertsson P, Jeppsson A. Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. Eur J Cardiothorac Surg 2014; 46 (04) 699-705 , discussion 705
• 5 Sousa-Uva M, Milojevic M, Head SJ, Jeppsson A. The 2017 EACTS guidelines on perioperative medication in adult cardiac surgery and patient blood management. Eur J Cardiothorac Surg 2018; 53 (01) 1-2
• 6 Shafiq A, Jang JS, Kureshi F. et al. Predicting likelihood for coronary artery bypass grafting after non-ST-elevation myocardial infarction: finding the best prediction model. Ann Thorac Surg 2016; 102 (04) 1304-1311
• 7 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
• 8 Bovill EG, Terrin ML, Stump DC. et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991; 115 (04) 256-265
• 9 Kremke M, Gissel MS, Jensen MJ, Thomassen SA, Jakobsen CJ. The association between a three-day ticagrelor discontinuation and perioperative bleeding complications. Eur J Cardiothorac Surg 2019; 55 (04) 714-720
• 10 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
• 11 Dyke C, Aronson S, Dietrich W. et al. Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg 2014; 147 (05) 1458-1463.e1
• 12 Sanfilippo F, Knight JB, Scolletta S. et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care 2017; 21 (01) 252
• 13 Hansson EC, Jidéus L, Åberg B. et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 2016; 37 (02) 189-197
• 14 Hoxha A, Shehu S, Deveja R, Qirjazi T. Impact of clopidogrel loading for coronarography on bleeding after urgent first time CABG. Med Arh 2018; 72 (05) 319-324
• 15 Miceli A, Duggan SM, Aresu G. et al. Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 2013; 43 (04) 722-728
• 16 Gili S, D'Ascenzo F, Lococo MF. et al. Impact of blood transfusion on in-hospital myocardial infarctions according to patterns of acute coronary syndrome: insights from the BleeMACS registry. Int J Cardiol 2016; 221: 364-370
• 17 Straus S, Haxhibeqiri-Karabdic I, Grabovica SG, Granov N. A difference in bleeding and use of blood and blood products in patients who were preoperatively on aspirin or dual antiplatelet therapy before coronary artery bypass grafting. Med Arh 2018; 72 (01) 31-35
• 18 Koster A, Zittermann A, Börgermann J. et al. Transfusion of 1 and 2 units of red blood cells does not increase mortality and organ failure in patients undergoing isolated coronary artery bypass grafting. Eur J Cardiothorac Surg 2016; 49 (03) 931-936
• 19 Kremke M, Hansen MK, Christensen S, Tang M, Andreasen JJ, Jakobsen CJ. The association between platelet transfusion and adverse outcomes after coronary artery bypass surgery. Eur J Cardiothorac Surg 2015; 48 (05) e102-e109
• 20 Mariscalco G, Biancari F, Juvonen T. et al. Red blood cell transfusion is a determinant of neurological complications after cardiac surgery. Interact Cardiovasc Thorac Surg 2015; 20 (02) 166-171
• 21 Petricevic M, Petricevic M, Pasalic M. et al. Cost analysis of transfusion therapy in coronary artery surgery. Thorac Cardiovasc Surg 2019; DOI: 10.1055/s-0039-1697600.
• 22 Hassan K, Kannmacher J, Wohlmuth P, Budde U, Schmoeckel M, Geidel S. Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding. Ann Thorac Surg 2019; 108 (01) 45-51
• 23 Angheloiu GO, Gugiu GB, Ruse C, Pandey R, Dasari RR, Whatling C. Ticagrelor removal from human blood. JACC Basic Transl Sci 2017; 2 (02) 135-145
• 24 Bhatt DL, Pollack CV, Weitz JI. et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med 2019; 380 (19) 1825-1833
• 25 Kubo T, Ino Y, Matsuo Y. et al. Reduction of in-stent thrombus immediately after percutaneous coronary intervention by pretreatment with prasugrel compared with clopidogrel: an optical coherence tomography study. J Cardiol 2017; 69 (02) 436-441
• 26 Yudi MB, Clark DJ, Farouque O. et al; Melbourne Interventional Group. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J 2016; 46 (05) 559-565
• 27 Becker RC, Bassand JP, Budaj A. et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011; 32 (23) 2933-2944
• 28 Goodnough LT, Smith PK, Levy JH. et al. Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg 2013; 145 (04) 1077-1082.e4
• 29 Smith PK, Goodnough LT, Levy JH. et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012; 60 (05) 388-396